CU23435A1 - NMB2134 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONS - Google Patents
NMB2134 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONSInfo
- Publication number
- CU23435A1 CU23435A1 CU20030287A CU20030287A CU23435A1 CU 23435 A1 CU23435 A1 CU 23435A1 CU 20030287 A CU20030287 A CU 20030287A CU 20030287 A CU20030287 A CU 20030287A CU 23435 A1 CU23435 A1 CU 23435A1
- Authority
- CU
- Cuba
- Prior art keywords
- nmb2134
- protein
- formulations
- inducing
- antigen
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 241000588650 Neisseria meningitidis Species 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 238000012163 sequencing technique Methods 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Uso de un nuevo antígeno vacunal aplicado de manera preventiva o terapéutica contra enfermedades bacterianas, virales, cancerosas, o de otro origen. El objetivo técnico que se persigue es el desarrollo de formulaciones capaces de elevar el espectro protector de las vacunas ya existentes y extenderlo contra diferentes patógenos. Para lograr este objetivo se aisló e identificó la proteína NMB2134 como componente de las preparaciones de membrana externa de Neisseria meningitidis, capaz de inducir actividad bactericida. Adicionalmente, se clonó y expresó el gen codificante para la proteína NMB2134, la cual se purificó evaluándose luego se inmunogenicidad en biomodelos animales. El secuenciamiento de genes homólogos evidenció, por su elevado grado de conservación, su alto valor como antígeno inductor de una respuesta inmune cruzada cuando es presentado por diferentes vías. Las formulaciones resultantes de esta invención son aplicables en la industria farmacéutica como formulaciones vacúnales para uso humano.Use of a new vaccine antigen applied in a preventive or therapeutic way against bacterial, viral, cancerous or other diseases. The technical objective pursued is the development of formulations capable of raising the protective spectrum of existing vaccines and extending it against different pathogens. To achieve this objective, the NMB2134 protein was isolated and identified as a component of Neisseria meningitidis external membrane preparations, capable of inducing bactericidal activity. Additionally, the gene coding for the NMB2134 protein was cloned and expressed, which was purified and then evaluated for immunogenicity in animal biomodels. The sequencing of homologous genes evidenced, due to its high degree of conservation, its high value as an antigen inducing a cross-immune response when presented by different routes. The formulations resulting from this invention are applicable in the pharmaceutical industry as vaccine formulations for human use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20030287A CU23435A1 (en) | 2003-12-03 | 2003-12-03 | NMB2134 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20030287A CU23435A1 (en) | 2003-12-03 | 2003-12-03 | NMB2134 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU23435A1 true CU23435A1 (en) | 2009-10-16 |
Family
ID=41320029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20030287A CU23435A1 (en) | 2003-12-03 | 2003-12-03 | NMB2134 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONS |
Country Status (1)
| Country | Link |
|---|---|
| CU (1) | CU23435A1 (en) |
-
2003
- 2003-12-03 CU CU20030287A patent/CU23435A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1117757T1 (en) | MODIFIED RSV F PROTEINS AND METHODS OF USE | |
| NO20111324A1 (en) | Recombinant MVA virus | |
| NO20054608L (en) | Influenza vaccine | |
| AR083561A1 (en) | PREPARATION OF AN ANTIGENIC CONSTRUCTION | |
| PH12012500756A1 (en) | Peptides used in the treatment and/or care of the skin, mucous membranes and/or hair and its use in cosmetic or pharmaceutical compositions | |
| CY1111916T1 (en) | VACCINATED VACCINATED ROTAIUS VACCINE FOR ADMINISTRATION OF THE ORAL | |
| CL2009000445A1 (en) | Compounds derived from piperidine 1,4 heterocycle substituted, procedure to prepare these compounds, pharmaceutical composition comprising them and their use for pain therapy and the treatment of diseases such as Alzheimer's, schizophrenia, anxiety and depression. | |
| CY1117584T1 (en) | 1-Benzyl-3-hydroxymethyldazole derivative and their use in the therapeutic treatment of MCP-1-expressing MC3-C3 | |
| WO2009009759A3 (en) | Yersinia pestis antigens, vaccine compositions, and related methods | |
| CO6460752A2 (en) | IMMUNE RESPONSE REINFORCED IN AVIAN SPECIES | |
| AR046937A1 (en) | PROTEIN NMB0928 AND ITS USE IN PHARMACEUTICAL FORMULATIONS | |
| MX2023007229A (en) | Rna construct. | |
| DE60336588D1 (en) | IMPROVED ANTHRAXIMP AND METHOD OF DELIVERY | |
| EA200700656A1 (en) | STABLE LIQUID PLASMID DNA COMPOSITIONS | |
| CU23435A1 (en) | NMB2134 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONS | |
| CU23419A1 (en) | NMB0088 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONS | |
| CU23237A1 (en) | PROTEIN NMB1125 AND ITS USE IN PHARMACEUTICAL FORMULATIONS | |
| CY1107560T1 (en) | LIVING DESTROYED BACTERIA FOR USE IN THE VACCINE | |
| WO2003101482A3 (en) | Liposome vaccine formulations for fin-fish | |
| BRPI0516963A (en) | nucleic acid, plasmid, veterinary composition, vaccine, methods of protecting poultry from campylobacter colonization and protecting a human from campylobacter infection, use of a nucleic acid, a plasmid, a composition, or a vaccine, and, food | |
| BR112014007491A2 (en) | amino acid sequences for pathogen control | |
| ATE457997T1 (en) | VACCINE AGAINST BURKHOLDERIA INFECTIONS | |
| DK2384761T3 (en) | Modified rodent parvovirus capable of propagating and spreading in human gliomas | |
| AR046921A1 (en) | METHOD FOR THE INCORPORATION OF ANTIGENS IN EXTERNAL MEMBRANE VESICULES OF BACTERIA AND RESULTING FORMULATIONS | |
| AR060796A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING PROTEIN NMB0938 |